Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors - Takeaways - MDSpire

Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors

  • By

  • Jack M. Shireman

  • Elliot Xie

  • Connie S. Lebakken

  • Sudarshawn Damodharan

  • Kailyn T. Parham

  • William D. Richards

  • Rintaro Hashizume

  • Christina Kendziorski

  • Mahua Dey

  • May 7, 2026

  • 0 min

Share

  • 1

    Diffuse midline gliomas (DMGs) develop in a complex tumor microenvironment (TME) that influences tumor behavior and therapeutic responses.

  • 2

    Traditional in-vitro models fail to accurately represent the TME, leading to gaps in preclinical research for CNS tumors.

  • 3

    Human planar neural organoids (PNOs) can be seeded with patient-derived xenograft (PDX) cell lines, providing a more accurate model for studying DMGs.

  • 4

    PNOs replicate genetic signatures and transcriptomic landscapes of patient tumors, making them superior for drug screening and toxicity assessments.

  • 5

    The study validates the use of PNOs as a scalable human-based modeling system to enhance preclinical testing and reduce reliance on animal models.

Original Source(s)

Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors

  • by Jack M. Shireman, Elliot Xie, Connie S. Lebakken, Sudarshawn Damodharan, Kailyn T. Parham, William D. Richards, Rintaro Hashizume, Christina Kendziorski, Mahua Dey

  • May 7, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms